Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: Introduction. Secondary lymphedema following cancer therapy is a frequent, often painful, quality of life disturbing condition, reducing the patients' mobility and predisposing them to complications, e.g. infections and malignancies. The critical aspect of lymphedema therapy is to start as soon aspossible to prevent the irreversible tissue damage. Patients and methods. Weperformed a retrospective study of patients with lymphedema, treated at the Department of Dermatovenereology, University Medical Center Ljubljana, from January 2002 to June 2010. The patientsć demographic and medical data were collected, including type of cancer, type and stage of lymphedema, and time tofirst therapy of lymphedema. The number of referred patients with lymphedema following the therapy of melanoma, breast cancer, and uterine/cervical cancer, was compared to the number of patients expected to experience lymphedema following cancer therapy, calculated from the incidence reported in the literature. Results. In the period of 8.5 years, 543 patients (432 females, 112 males) with lymphedema were treated. The results show that probably many Slovenian patients with secondary lymphedema following cancer therapy remain unrecognized and untreated or undertreated. In the majority of our patients, the management of lymphedema was delayedč on average, the patients first received therapy for lymphedema 3.6 years after the first signsof lymphedema. Conclusions. To avoid a delay in diagnosis and therapy, and the complications of lymphedema following cancer therapy, the physician should actively look for signs or symptoms of lymphedema during the follow-up period, and promptly manage or refer the patients developing problems.
Ključne besede: rak (medicina), zdravljenje, limfedem
Objavljeno v DiRROS: 18.03.2024; Ogledov: 135; Prenosov: 38
Celotno besedilo (416,52 KB)

Povzetek: Background. Light microscopic evaluation of cell morphology in preparations from urine or bladder washing containing exfoliated cells is a standard and primary method for the detection of bladder cancer and also malignancy from other parts of the urinary tract. The cytopathologic examination is a valuablemethod to detect an early recurrence of malignancy or new primary carcinoma during the follow-up of patients after the treatment of bladder cancer. Conclusions. Characteristic cellular and nuclear signs of malignancy indicate invasive or in situ urothelial carcinoma or high-grade papillary urothelial carcinoma. However, low sensitivity of the method reflects the unreliable cytopathologic diagnosis of low-grade urothelial neoplasms as cellular and nuclear signs of malignancy in these neoplasms are poorly manifested. Many different markers were developed to improve the diagnosis of bladder carcinoma on urinary samples. UroVysionT test is among the newest and most promising tests. By the method of in situ hybridization one can detect specific cytogenetic changes of urothelial carcinoma.
Ključne besede: rak (medicina), diagnostika, citološka diagnostika, sečni mehur
Objavljeno v DiRROS: 18.03.2024; Ogledov: 127; Prenosov: 38
Celotno besedilo (589,07 KB)

Ključne besede: rak (medicina), tumor, zdravljenje, citostatiki, tumorski nekrozni faktor
Objavljeno v DiRROS: 15.01.2024; Ogledov: 267; Prenosov: 63
Celotno besedilo (1,03 MB)

Ključne besede: rak (medicina), dojke, diagnostika
Objavljeno v DiRROS: 15.01.2024; Ogledov: 266; Prenosov: 69
Celotno besedilo (407,58 KB)

Ključne besede: dojke, rak (medicina), prognoza
Objavljeno v DiRROS: 15.01.2024; Ogledov: 212; Prenosov: 61
Celotno besedilo (334,34 KB)